myasthenia gravis market globaldata.com

Myasthenia Gravis (MG) is a relatively rare, acquired, chronic, autoimmune neuromuscular disease caused by an antibody-mediated blockade at the neuromuscular transmission, resulting in skeletal muscle weakness and rapid muscle fatigue. In many adults with MG, the thymus gland remains large. People with the disease typically have clusters of immune cells in their thymus gland and may develop thymomas (tumors of the thymus gland).

The myasthenia gravis marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for myasthenia gravis (MG).